Top

BY Scott Merville

A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer cells for destruction by the immune system.

Writing this month in Nature Immunology, a team led by scientists at MD Anderson shows that the long, non-coding RNA (lncRNA) called LINK-A is a potential therapeutic target for triple negative breast cancer.

Working in a uniquely developed...

CD8-positive immune system T cells attacking cancer cells.

BY Devon Carter

Triple-negative breast cancer (TNBC) makes up 15 to 20 percent of breast cancer diagnoses. The condition often is considered a single disease...

BY Ron Gilmore

Triple-negative breast cancer (TNBC) is an aggressive form of the disease that doesn’t rely on the hormones estrogen and progesterone or the...

BY Ron Gilmore

Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone disease that accounts for one-fourth of all breast cancers, could potentially be treated with immune checkpoint blockade therapy.

Already used to treat other cancers, immune checkpoint blockade therapy relies on connections between PD-L1 and its sister molecule, PD1, found on T-cell surfaces, allowing cancer cells to go undetected by the immune system. Blocking...

T cells attack breast cancer after treatment with radiation and an immune checkpoint blockade therapy

BY Ron Gilmore

When triple-negative breast cancer is still in its earliest, pre-cancerous stages, the tumor suppressor miRNA-29c becomes progressively deactivated...

BY Laura Sussman

In a pilot study conducted at MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved...

BY MD Anderson staff

A new trial underway at MD Anderson may lead to new therapies for triple negative breast cancer.

Fifteen to 20% of breast cancers...

BY Ron Gilmore

MD Anderson Cancer Center has been awarded $19.1 million in research grants in the most recent round of funding from the Cancer...

BY Ronda Wendler

An MD Anderson study is seeking new drugs to combat triple-negative breast cancer, an aggressive form of the disease that doesn’t rely on...

BY Ron GIlmore

In cancer, cell signaling pathways are the critical chain of events that can either quash or quicken disease progression.

A multi-institutional...